Table 3 Results of CHOP vs MACOP-B/VACOP-B in 138 consecutive patients according to IPI

From: Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B

 

CHOP

MACOP-B/VACOP-B

P

Low/low-intermediate risk

Patients

33/43 (76.7%)

74/95 (77.8%)

n.s.

CR/NCR

17/33 (51.5%)

62/74 (83.7%)

P=0.001

PR

1/33

6/74 (8%)

n.s.

NR/PD

15/33 (45.4%)

6/62 (9.6%)

P=0.001

REL

3/17 (17.6%)

5/62 (8%)

n.s.

Event-free patients

14/33 (42.4%)

60/74 (81%)

P<0.001

High-intermediate/high risk

Patients

10/43 (23.2%)

21/95 (22.1%)

n.s.

CR/NCR

5/10 (50%)

14/21 (66.6%)

n.s.

PR

2/10 (20%)

4/21 (19%)

n.s.

NR/PD

3/10 (30%)

3/21 (14.2 %)

n.s.

REL

2/5 (40%)

1/21 (4.7%)

n.s

Event-free patients

3/10 (30%)

12/21 (57.1%)

n.s.

Back to article page